Overview

• Introduction
• Disclaimer
• Certification

Summary

• Outline Slide
• Summary of Findings
• Summary of Findings by Segment
• Research Scope and Methodology
• Competitive Framework
• Technology Evolution Trajectory
• Potential Threats

Strategic Analysis

• Outline Slide
• Market Segmentation
• Market Drivers
• Market Restraints
• Industry Challenges
• Existing Companies
• Existing Products

Competitive Landscape

• Outline Slide
• Pipeline Therapeutic Trends
• Value of Biotech Out-License Deals
• Average Size of Biotech Out-License Deals
• Average Size of Biotech Out-License Deals by Payment Class
• Average Size of Biotech Out-License Deals by Stage
• U.S. Drug Approval Process

Phase I Pipeline Analysis

• Outline Slide
• Clinical Development Slide
• R1550 (Antisoma)
• Panzem (EntreMed)
• CEA-Cide (Immunomedics)
• Executive Quote (Immunomedics)
• HER-2/neu Vaccine (Corixa)
• BrevaRex (AltaRex)

Phase II Pipeline Analysis A

• Outline Slide
• Clinical Development Slide
• APC8024 (Dendreon)
• Executive Quote (Dendreon)
• Advexin (Introgen)
• Iressa (AstraZeneca)
• Zarnestra (Johnson & Johnson)
• Telcyta (Telik)
• TriAb (Titan Pharmaceuticals)
• INGN 225 (Introgen)
• Xyotax (Cell Therapeutics)
• BMS-275291 (Bristol-Myers Squibb)
• ERA-923 (Wyeth)

Phase II Pipeline Analysis B

• Omnitarg (Genentech)
• CI-1033 (Pfizer)
• CCI-779 (Wyeth)
• LEP/LED (NeoPharm)
• Alimta (Lilly)
• Genasense (Genta)

Phase III Pipeline Analysis A

• Outline Slide
• Clinical Development Slide
• Enhanzyn (Corixa)
• Avastin (Genentech)
• Doxil (Alza)
• Arzoxifene (Eli Lilly)
• GW-572016 (GlaxoSmithKline)
• Atamestane (BioMedicines)
• Tavocept (BioNumerik)
• Evista (Eli Lilly)
• Gemzar (Eli Lilly)
• Herceptin (Genentech)

Phase III Pipeline Analysis B

• Lasofoxifene (Pfizer)
• Navelbine (GlaxoSmithKline)
• Theratope (Biomira)
• Executive Quote (Biomira)
• 109881-Taxoid (Aventis)
• Celebrex (Pfizer)
• Xeloda (Roche)
• Tesmilifene (YM Biosciences)
• Executive Quote (YM Biosciences)

Company Analysis

• Outline Slide
• AltaRex and Alza
• Antisoma and AstraZeneca
• Aventis and BioMedicines
• BioMira and BioNumerik
• Bristol-Myers Squibb and CellTech
• Cell Therapeutics and Corixa
• Dendreon and EntreMed
• Genentech and Genta
• GlaxoSmithKline and Immunomedics
• Introgen Therapeutics and Johnson & Johnson
• Ligand Pharmaceuticals and Eli Lilly
• NeoPharm and Pfizer
• Roche and Telik
• Titan Pharmaceuticals and Wyeth
• YM Biosciences

Decision Support Databases

• Outline Slide
• Breast Cancer Incidence A
• Breast Cancer Incidence B
• Biotechnology Companies A
• Biotechnology Companies B
• Pharmaceutical R&D Expenditure A
• Pharmaceutical R&D Expenditure B

Frost & Sullivan Awards

• Outline Slide
• Introduction to Frost & Sullivan Awards
• Growth Strategy of the Year Award
• Innovative Technology Leadership of the Year Award
• Business Development Strategy Leadership of the Year Award
• Biotechnology Emerging Company of the Year Award

Frost & Sullivan

• Outline Slide
• Healthcare Team
• Our Capabilities
• Key Advantages
• Our Consulting Clients
• Frost & Sullivan Growth Consulting
• Growth Consulting Process
• Growth Consulting Deliverables
• Growth Partnership Services
• Growth Partnership Service Platform